MAIA Biotechnology, Inc.
MAIA- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001878313
In the last 90 days, MAIA Biotechnology, Inc. insiders filed 5 open-market purchases and 0 sales; 36 institutions reported holding it in 13F filings for Q2 2026, worth $19.4M in total; no superinvestor holds it.
Key figures
- Insider buysLast 90 days, $352.3K in total
- 5
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, +3 vs. previous quarter
- 36
- 13F valueReported value at the end of Q2 2026
- $19.4M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding MAIA, Q2 2026
No superinvestor reported holding MAIA at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by MAIA Biotechnology, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 15, 2026 (view filing)6:33 AM ET | Sep 14 | 1 day | Vitoc VladChief Executive Officer | PPurchase | +73.0K | $1.37 | +$100.0K | +7.5%1.05M after | |
| Sep 14, 2026 (view filing)9:03 AM ET | Sep 10 | 4 days | Guerrero RamiroDirector | PPurchase | +37.6K | $1.32 | +$49.5K | +5.1%773.3K after | |
| Sep 1, 2026 (view filing)4:16 PM ET | Aug 26-28 | 6 daysLate | Guerrero RamiroDirector | PPurchase | +133.8K | $1.38 | +$184.1K | +22.2%735.7K after | 3 lots |
| Aug 26, 2026 (view filing)7:56 AM ET | Aug 24 | 2 days | Guerrero RamiroDirector | PPurchase | +1.79K | $1.33 | +$2.39K | +0.3%601.9K after | |
| Aug 24, 2026 (view filing)4:09 PM ET | Aug 20 | 4 days | Guerrero RamiroDirector | PPurchase | +11.9K | $1.37 | +$16.3K | +2.0%600.1K after | |
| Jun 2, 2026 (view filing) | Jun 1 | 1 day | Vitoc VladChief Executive Officer | PPurchase | +72.7K | $1.39 | +$101.1K | +8.0%976.1K after | |
| Jun 2, 2026 (view filing) | Jun 1 | 1 day | Smith StanDirector | PPurchase | +75.0K | $1.34 | +$100.5K | +5.2%1.52M after | |
| Jun 2, 2026 (view filing) | Jun 1 | 1 day | Gryaznov SergeiChief Scientific Officer | PPurchase | +2.00K | $1.35 | +$2.70K | +4.5%46.5K after | |
| Jan 12, 2026 (view filing) | Sep 19, 2022 | 1,211 daysLate | Smith StanDirector | PPurchase | +2.70K | $3.69 | +$9.96K | +0.2%1.42M after | |
| Dec 23, 2025 (view filing) | Dec 22 | 1 day | Smith StanDirector | PPurchase | +57.2K | $1.22 | +$69.8K | +4.2%1.42M after |
Top 10 13F holders, Q2 2026
The largest institutional positions in MAIA Biotechnology, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Solas Capital Management, LLC | 3,030,845 | $4.36M | 2.34% | −1,266,159−29.5% | Reduced |
| Alyeska Investment Group, L.P. | 2,500,000 | $3.60M | 0.01% | 00.0% | Unchanged |
| Vanguard Capital Management LLC | 2,413,270 | $3.48M | 0.00% | +339,225+16.4% | Added |
| 683 Capital Management, LLC | 1,066,666 | $1.54M | 0.14% | 00.0% | Unchanged |
| Centric Wealth Management | 796,723 | $1.11M | 0.17% | 00.0% | Unchanged |
| Cable Car Capital LLC | 514,583 | $741.0K | 0.02% | −133,920−20.7% | Reduced |
| Geode Capital Management, LLC | 504,380 | $726.6K | 0.00% | +143,899+39.9% | Added |
| Bleichroeder LP | 500,000 | $720.0K | 0.13% | 00.0% | Unchanged |
| Renaissance Technologies LLC | 415,700 | $598.6K | 0.00% | +415,700 | New |
| BlackRock, Inc. | 403,011 | $580.3K | 0.00% | +275,033+214.9% | Added |